Clinical trials: Advanced Solid Tumors (Phase 1)
Advanced or Metastatic Solid Tumors
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
The purpose of this study is to see if TAS0612 is safe in participants with advanced or metastatic solid tumor cancer.
- Trial name
- NCT04586270
- Testing
- TAS0612
- Where
- 4 sites in United States, France
- Volunteers
- 47 people
- Sponsor
- Taiho Oncology, Inc.
Solid Tumor
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
The primary objectives of Phase 1A are to evaluate the safety of KITE-718, determine a recommended Phase 1B dose, and to evaluate the efficacy of KITE-718 in Phase 1B.
- Trial name
- NCT03139370
- Testing
- KITE-718, Cyclophosphamide, Fludarabine
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Kite, A Gilead Company
Advanced Solid Tumors
Study of ZGGS15 in Patients With Advanced Solid Tumors
This is a multi-center, open-label, Phase 1 clinical study of ZGGS15 for the treatment of patients with advanced solid tumors.
- Trial name
- NCT05864573
- Testing
- ZGGS15
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Cancer, Solid Tumor
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors.
- Conditions
- Cancer, Solid Tumor, Melanoma, Carcinoma
- Trial name
- NCT05708950
- Testing
- KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kineta Inc.
Solid Tumor, Adult
A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors
This is a multicenter, open label, dose escalation \& expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006.
- Trial name
- NCT03516123
- Testing
- CS3006
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- CStone Pharmaceuticals
Advanced Solid Tumors
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the effect of multiple-dose administration of fluconazole on the single-dose intravenous (IV) pharmacokinetics (PK) of MLN4924; and to assess the effect of multiple-dose…
- Trial name
- NCT02122770
- Testing
- MLN4924, Fluconazole, Itraconazole
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Solid Tumor
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ES009 administered intravenously to subjects with advanced solid tumors.
- Trial name
- NCT06007482
- Testing
- ES009
- Where
- 4 sites in Australia
- Volunteers
- 12 people
- Sponsor
- Elpiscience Biopharma Australia Pty. Ltd.
Neoplasms, Malignant
A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor
Primary Objectives: To determine the excretion balance and systemic exposure of radioactivity after intravenous infusion of [14C]-AVE8062 to humans To determine the pharmacokinetics of AVE8062 and RPR258063 and their contribution…
- Trial name
- NCT01063946
- Testing
- Ombrabulin (AVE8062)
- Where
- Belgium
- Volunteers
- 3 people
- Sponsor
- Sanofi
Advanced Solid Malignancy,, Safety and Tolerability,
Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability
Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability
- Conditions
- Advanced Solid Malignancy,, Safety and Tolerability,, Pharmacokinetics, Pharmacodynamics,, Tumour Response,
- Trial name
- OAK (NCT01895946)
- Testing
- AZD5363
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 33 people
- Sponsor
- AstraZeneca
Advance Solid Tumors, Advanced Malignant Solid Tumors
A Study of CS231295 in Patients With Advanced Solid Tumors
This is a Phase I, single-arm, open-label, dose-escalation, multicenter clinical study of CS231295 in patients with advanced solid malignant tumors.
- Trial name
- NCT07612488
- Testing
- a small molecular multi-target kinase inhibitor
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- ThalassaX Therapeutics United States Ltd
Neoplasms, Metastases, Neoplasm
A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies
This trial will treat patients with advanced (metastatic) cancer with a new chemotherapeutic agent that may be more readily tolerated than some standard therapies.
- Trial name
- NCT00046423
- Testing
- ABI-007
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Celgene Corporation
Advanced Solid Tumor
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with…
- Trial name
- NCT06682780
- Testing
- LM-2417, Docetaxel, Toripalimab/Tirelizumab
- Where
- China
- Volunteers
- 320 people
- Sponsor
- LaNova Medicines Limited
Advanced Solid Tumor, Lymphoma
Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors
T-1301 is a novel small-molecule inhibitor of multiple kinases being developed as an oral drug for the treatment of advanced solid tumors.
- Trial name
- NCT05156203
- Testing
- T-1301 Capsules
- Where
- 3 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Taivex Therapeutics Corporation
Solid Tumor, TNBC - Triple-Negative Breast Cancer
TH1902 in Patients With Advanced Solid Tumors
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard…
- Conditions
- Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT04706962
- Testing
- TH1902
- Where
- 6 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Theratechnologies
Solid Tumor and Lymphoma
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
The study will consist of a Phase I dose-escalation and Phase IIa dose-expansion component. Phase I dose-escalation phase will establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D),and evaluate the…
- Trial name
- NCT07333469
- Testing
- HX111 for injection
- Volunteers
- 70 people
- Sponsor
- Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Advanced Solid Tumors
A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
The purpose of the study is to determine whether amrubicin is safe and effective in the treatment of patients with advanced solid tumors.
- Trial name
- NCT00915083
- Testing
- Amrubicin
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Celgene
Breast Cancer, Breast Neoplasms
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors.
- Conditions
- Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer
- Trial name
- NCT00600496
- Testing
- AZD6244, Dacarbazine, Erlotinib
- Where
- 4 sites in United States
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Solid Tumors
A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors
Study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in participants with advanced solid tumors.
- Trial name
- NCT02667873
- Testing
- SL-801
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- Stemline Therapeutics, Inc.
Platinum-resistant Ovarian Cancer, Testicular Cancer
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with…
- Conditions
- Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
- Trial name
- NCT06515613
- Testing
- CTIM-76
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 156 people
- Sponsor
- Context Therapeutics Inc.
Advanced Solid Tumor
A Phase I Study of Famitinib Malate in Patients With Solid Tumor
Famitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study is designed to evaluate the safety and tolerability of Famitinib in patients with solid tumor
- Trial name
- NCT01762280
- Testing
- Famitinib Malate Capsule
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.